Bharat Biotech's iNNOVACC: India's 1st intranasal vaccine to cost Rs 800 in private markets, Rs 325 for govt

Bharat Biotech's iNNOVACC: India's 1st intranasal vaccine to cost Rs 800 in private markets, Rs 325 for govt iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion-stabilized SARS-CoV-2 spike protein. This vaccine candidate was evaluated in phases I, II and III clinical trials with successful results. https://ift.tt/lIYBNH0

Comments

Popular posts from this blog

SC transfers PIL seeking implementation of law on mental health care to NHRC

Hospital-insurer conflict: Will latest circular by NMC help in reducing the pain of health insurance policyholders?

Over 9.19 crore hospital admissions facilitated under Ayushman Bharat since 2018